Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis.

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Dupilumab, an IL-4/IL-13 inhibitor, is approved for moderate-to-severe atopic dermatitis (AD).
• Previous studies noted increased serum eosinophils during dupilumab treatment, but their clinical significance remains unclear.
• This study investigates changes in blood eosinophils and other lab parameters in AD patients receiving dupilumab.

Purpose of the Study:

• To evaluate the clinical significance of elevated eosinophil levels in patients with atopic dermatitis treated with dupilumab.
• To assess changes in blood eosinophil counts and other laboratory markers during dupilumab therapy for moderate-to-severe AD.
• To determine if increased eosinophils warrant treatment discontinuation.

Main Methods:

• A multicenter, prospective, observational study involving 81 adolescent and adult patients with moderate-to-severe AD.
• Data collected included clinical severity scores and laboratory parameters (complete blood count, total serum IgE, LDH) at baseline and weeks 8, 16, 24, and 48.
• Statistical analysis compared parameters at different time points during the 48-week treatment period.

Main Results:

• Patients showed sustained improvement in AD severity scales from week 8 onwards.
• Eosinophil levels significantly increased at week 16 compared to baseline (p=0.018) but returned to baseline by week 48.
• Lactate dehydrogenase (LDH) and immunoglobulin E (IgE) levels decreased during the study period.

Conclusions:

• Dupilumab treatment led to significant clinical improvement in atopic dermatitis.
• A mild, self-limited increase in eosinophil levels was observed at week 16, which was not associated with clinical symptoms.
• Elevated serum eosinophils in AD patients on dupilumab appear clinically irrelevant and should not be a reason to stop treatment.